Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its interim results for the six months ended 31 December 2024 on Tuesday, 11 March 2025.
Aptamer Group to publish interim results on Tuesday 11th March
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.
Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery.
Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount.
Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.
Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth.
Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market.
